Abstract
Cell therapy has been shown as a potential treatment for stroke and other neurological disorders. Human umbilical cord blood (HUCB) may be a promising source of stem cells for cell therapy. The most desired outcomes occur when stem cells cross the blood brain barrier (BBB) and eventually reach the injured brain site. We propose, from our previous studies, that mannitol is capable of disrupting the BBB, allowing the transplanted cells to enter the brain from the periphery. However, when the BBB is compromised, the inflammatory response from circulation may also be able to penetrate the brain and thus may actually exacerbate the stroke rather than afford therapeutic effects. We discuss how an NF-kB decoy can inhibit the inflammatory responses in the stroke brain thereby reducing the negative effects associated with BBB disruption. In this review, we propose the combination of mannitol-induced BBB permeation and NF-kB decoy for enhancing the therapeutic benefits of cell therapy in stroke.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3670-3676 |
| Number of pages | 7 |
| Journal | Current Pharmaceutical Design |
| Volume | 18 |
| Issue number | 25 |
| DOIs | |
| State | Published - Oct 22 2012 |
Fingerprint
Keywords
- Blood brain barrier
- Cerebral palsy
- Mannitol
- Neurotrophic factor
- NF-kB
- Stem cells
- Transplantation
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
Cite this
Permeating the blood brain barrier and Abrogating the inflammation in stroke : Implications for stroke therapy. / Borlongan, Cesar V.; Glover, Loren E.; Sanberg, P. R.; Hess, David C.
In: Current Pharmaceutical Design, Vol. 18, No. 25, 22.10.2012, p. 3670-3676.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Permeating the blood brain barrier and Abrogating the inflammation in stroke
T2 - Implications for stroke therapy
AU - Borlongan, Cesar V.
AU - Glover, Loren E.
AU - Sanberg, P. R.
AU - Hess, David C
PY - 2012/10/22
Y1 - 2012/10/22
N2 - Cell therapy has been shown as a potential treatment for stroke and other neurological disorders. Human umbilical cord blood (HUCB) may be a promising source of stem cells for cell therapy. The most desired outcomes occur when stem cells cross the blood brain barrier (BBB) and eventually reach the injured brain site. We propose, from our previous studies, that mannitol is capable of disrupting the BBB, allowing the transplanted cells to enter the brain from the periphery. However, when the BBB is compromised, the inflammatory response from circulation may also be able to penetrate the brain and thus may actually exacerbate the stroke rather than afford therapeutic effects. We discuss how an NF-kB decoy can inhibit the inflammatory responses in the stroke brain thereby reducing the negative effects associated with BBB disruption. In this review, we propose the combination of mannitol-induced BBB permeation and NF-kB decoy for enhancing the therapeutic benefits of cell therapy in stroke.
AB - Cell therapy has been shown as a potential treatment for stroke and other neurological disorders. Human umbilical cord blood (HUCB) may be a promising source of stem cells for cell therapy. The most desired outcomes occur when stem cells cross the blood brain barrier (BBB) and eventually reach the injured brain site. We propose, from our previous studies, that mannitol is capable of disrupting the BBB, allowing the transplanted cells to enter the brain from the periphery. However, when the BBB is compromised, the inflammatory response from circulation may also be able to penetrate the brain and thus may actually exacerbate the stroke rather than afford therapeutic effects. We discuss how an NF-kB decoy can inhibit the inflammatory responses in the stroke brain thereby reducing the negative effects associated with BBB disruption. In this review, we propose the combination of mannitol-induced BBB permeation and NF-kB decoy for enhancing the therapeutic benefits of cell therapy in stroke.
KW - Blood brain barrier
KW - Cerebral palsy
KW - Mannitol
KW - Neurotrophic factor
KW - NF-kB
KW - Stem cells
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=84867535127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867535127&partnerID=8YFLogxK
U2 - 10.2174/138161212802002841
DO - 10.2174/138161212802002841
M3 - Review article
VL - 18
SP - 3670
EP - 3676
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
SN - 1381-6128
IS - 25
ER -